Systemic infection by encapsulated organisms, such as for example serogroup C. to the structure of their capsular polysaccharides.8C10 To date, 13 serogroups have been identified; however, four serogroups, namely A, B, C and Y, account for 90% of meningococcal meningitis cases.5,7 In the United States, serogroup C alone is responsible for 45% of the cases of meningococcal meningitis each year.7 The group C meningococcal polysaccharide vaccine is based on the observation that antibodies directed at the polysaccharide capsule protect against disease by inducing complement-dependent bactericidal activity.11C14 Although it is currently recommended for controlling meningococcal outbreaks and epidemics, the polysaccharide vaccine has several limitations. First, group C polysaccharide fails to elicit Givinostat protective levels of antibodies in children < 2 years of age, the age-group with the highest incidence, morbidity and mortality. Second, reimmunization in this age-group causes suppression, rather than enhancement, of the immune response.15C17 The poor efficacy and limited duration of the immune response in young children is attributed to the T-independent nature of the polysaccharide vaccine, as the response to these antigens develops late in ontogeny.18C20 A polysaccharideCprotein conjugate Givinostat converts group C polysaccharide from a T-cell independent antigen into an immunogenic and effective vaccine at all ages.21C26 Limitations of conjugates are the Givinostat Givinostat requirement of at least three, and possibly four, immunizations in infancy to achieve optimal efficacy. In addition, studies have shown that this antibody response to the polysaccharide component of the conjugate continues to possess characteristics of a Mouse monoclonal to IgG2a Isotype Control.This can be used as a mouse IgG2a isotype control in flow cytometry and other applications. T-independent immune response.27C29 An alternative approach to the development of a T-dependent immune response to a carbohydrate is the use of anti-idiotypic (anti-Id) immunoglobulins that mimic the polysaccharide.30C33 Anti-Id immunoglobulins can become surrogate images from the carbohydrate antigen and will induce an operating, carbohydrate antibody response.34,35 Previously, we identified an anti-Id immunoglobulin that mimics the polysaccharide of serogroup C.36 This anti-Id immunoglobulin elicited a T-dependent anti-polysaccharide antibody response that was protective in animal research.36,37 Further immunization research demonstrated a peptide, spanning the immunogenic CDR3 region from the anti-Id immunoglobulin, when complexed to proteosomes induced security against a lethal challenge with meningococci.38 These findings illustrate a peptide imitate of the capsular polysaccharide can induce a T-dependent immune response. An all natural extension from the observation that peptides can imitate polysaccharides may be the advancement of DNA constructs that creates polysaccharide antibodies. DNA immunization is dependant on the idea that endogenous appearance of the encoded peptide by web host cell equipment will Givinostat stimulate an immune system response similar compared to that induced with a pathogen.39C41 Several research have demonstrated the benefits of DNA immunization.42,43 Initial, DNA vaccines are cheap to make and constructed easily. Second, DNA vaccines are thermally steady at high and low temperatures, avoiding the need for cold-chain transport. This is essential for delivering the vaccine to areas of endemic disease. Third, DNA vaccines are malleable and can be altered to modulate the magnitude and orientation of the immune response.44C46 This allows the insertion of multiple DNA-encoded epitope sequences, representing protein as well as carbohydrate antigens, into the DNA vector.47C51 An advantage of this approach is the induction of a multispecific immune response directed at numerous immunologically relevant epitopes.52,53 The ability to modulate the immune response to specific protein and carbohydrate epitopes makes DNA vaccines ideal for use against encapsulated organisms, where antibodies can be directed at both the polysaccharide and relevant protein epitopes. Including epitopes that encode peptide mimics of various serogroup polysaccharides, and those encoding conserved cell-wall components (i.e. proteins), allows the construction of a multiepitope DNA vaccine that has the potential of protecting against numerous meningococcal strains. In this present study, we constructed a multiepitope DNA vaccine, encoding a peptide mimic of meningococcal serogroup C capsular polysaccharide (MCPS), a universal T-cell helper epitope, and a secretory leader sequence. Immunization with this DNA construct resulted in a functional anti-MCPS antibody response. Live challenge studies.